Letters to the Editor
- 23 April 2003
- journal article
- research article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 28 (2) , 151-153
Abstract
Click on the article title to read more.Keywords
This publication has 14 references indexed in Scilit:
- An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndromeGut, 2003
- Tegaserod, a 5‐HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjectsAlimentary Pharmacology & Therapeutics, 2003
- A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipationAlimentary Pharmacology & Therapeutics, 2002
- A systematic review of tegaserod for the treatment of irritable bowel syndromeJournal of Clinical Pharmacy and Therapeutics, 2002
- Long‐term safety of tegaserod in patients with constipation‐predominant irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2002
- Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effectsAmerican Journal of Gastroenterology, 2002
- Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptomsAmerican Journal of Gastroenterology, 2002
- Persistent placebo response during a year-long controlled trial of IBS treatmentGastroenterology, 2001
- Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in ratsGastroenterology, 2000
- Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserodGastroenterology, 2000